

Reinstatement of the Medi-Cal Rx Controlled Substance Policy on Buprenorphine Products

May 1, 2023

What Pharmacy Providers and Prescribers Need to Know

On January 30, 2023, the Biden Administration announced that the COVID-19 Public Health Emergency (PHE) is set to end on May 11, 2023. As a result, on June 1, 2023, Buprenorphine products for pain or addiction will no longer have the option to be filled for up to 100 days supply without a prior authorization (PA). Starting June 1, 2023, all Buprenorphine products may be filled up to a 35-day supply.

What Pharmacy Providers and Prescribers Need to Do

Pharmacy providers and prescribers are encouraged to review the Controlled Substance Policy located in the <u>Medi-Cal Rx Contract Drugs List (CDL)</u>.

Contact Information

You can call the Medi-Cal Rx Customer Service Center (CSC) at 1-800-977-2273, which is available 24 hours a day, 7 days a week, 365 days per year.

For other questions, email Medi-Cal Rx Education & Outreach at <u>MediCalRxEducationOutreach@magellanhealth.com</u>